- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Terrill Jordan: The Promise, and the Reality, of Biosimilars
Terrill Jordan, chief executive officer of Regional Cancer Care Associates (RCCA), discusses how RCCA is handling biosimilar availability.
Transcript
Biosimilars, you know, there's a lot of promise there. What we found at [Regional Cancer Care Associates, RCCA] when we looked at biosimilars is that the promise was probably more than what we'll actually see in practice. Biosimilars that take a lot of money to develop, at the end of the day, they're in the same place, many times, as the reference drug, maybe 15% to 20% cheaper.
So it's not the move you would expect from a value-based standpoint. So what I really expect we’ll see is that pricing will stabilize when you have a biosimilar because it will introduce competition, but I don't expect we'll see significant price decreases. These are not generics. So [with] a generic, the price will drop precipitously. We're not going to see that. We’ll see stabilization of price because of the competition. The more biosimilars in a particular category, the more, I think, stabilization you'll see.
So I think that's what we'll see. From our perspective, I actually just talked about our chairman this morning, and one of the things that we're looking at is, you know, how can we kind of push the value out of it? And that will be the piece that we’ll continue to kind of struggle with: how do we pull value out of that, instead of just price stability?
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
